CAS: 77-59-8; Tomatidine

上下游产品

dihydrotomatidine A N-Chlorotomatidine trifluoroacetic acid tomatineO,N-Diacetyl-tomatidin tomatidine acetate demissidine

Tomatidine Acetate置于sodium Hydroxide体系中,用 甲醇,二氯甲烷,水 作为反应溶剂,化学反应 2.0H,以95%的收率获得产物番茄碱
参考文献:革兰氏合成番茄碱,一种类固醇生物碱,具有对金黄色葡萄球菌持续存在的抗药性
标题:革兰氏合成番茄碱,一种类固醇生物碱,具有对金黄色葡萄球菌持续存在的抗药性
摘要:通过将手性有机锂片段加到衍生自市售薯os皂苷元的受保护的二降胆酸内酯中,茄类生物碱番茄碱的首次合成以24.9%(最长的线性序列)实现.这种方法使多谱图合成成为可能,其目标是支持其针对持久性金黄色葡萄球菌的抗生素特性的进一步研究.
DOI:10.1002/ejoc.202000051

专利信息

专利号:US-5455157-A
优先权日:1989-05-22
标 题:Method for the non-radioactive measurement of the nucleic acid synthesis in eukaryotic cells
发明人：HINZPETER MATTHIAS; ELTZ HERBERT VON DER
权利人:BOEHRINGER MANNHEIM GMBH
摘要:For the determination of the rate of nucleic acid synthesis in eukaryotic cells a nucleotide which is non-radioactively labelled or derivatized with a hapten is introduced into the cells with the addition of liposomes and the rate of synthesis of the nucleic acids is determined by means of the incorporation of the nucleotide via its label or derivatization.

专利号:US-12427148-B2
优先权日:2018-04-28
标 题:Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
发明人：RUGGERO DAVIDE; NGUYEN HAO; CARROLL PETER; CONN CRYSTAL
权利人:UNIV CALIFORNIA
摘要:In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2α axis of the UPR adaptive response. Agents that disrupt PERK-eIF2α pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.

专利号:US-2009012013-A9
优先权日:2003-07-08
标题 :Steroid modified solatrioses
发明人：LAWSON CHRISTOPHER J; WEYMOUTH-WILSON ALEXANDER C
权利人:LAWSON CHRISTOPHER J; WEYMOUTH-WILSON ALEXANDER C
摘要:The invention pertains to steroid modified solatrioses and the synthesis thereof as well as to intermediate compounds useful for the synthesis of the steroid modified solatrioses.

专利号:EP-1654271-B1
优先权日:2003-07-08
标题:Steroid modified solatrioses
发明人：LAWSON CHRISTOPHER JOHN; WEYMOUTH-WILSON ALEXANDER CHARLES
权利人:GLYCOMED SCIENCES LTD
摘要:The present invention relates to steroid modified chacotrioses and the synthesis thereof as well as to intermediate compounds useful for the synthesis of the steroid modified chacotrioses and solatrioses. Moreover, the present inventions relates to a method for the preparation of steroid-modified solatrioses.

专利号:US-10842834-B2
优先权日:2016-01-06
标题:Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
发明人：KOVARIK JOSEPH E
权利人:KOVARIK JOSEPH E
摘要:A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and may also be encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered, or a composition comprising modified L. reuteri bacteria having the ability to survive conditions in the duodenum or jejunum of the individual's small intestine. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Veillonella, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and Prevotella.

专利号:US-2025281557-A1
优先权日:2024-03-08
标 题:Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy
发明人：LI YINGZHONG; ZHANG LIBIN
权利人:SUNVAX MRNA THERAPEUTICS INC
摘要:The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncolytic defective virus compositions and methods of in vivo synthesis thereof. The composition includes a first nucleic acid construct encoding a self-amplifying mRNA (sa-mRNA) encoding at least one gene of interest (GOI) or a plurality of GOIs, a second nucleic acid construct encoding an mRNA encoding at least one virus structural protein, and at least one payload delivery system.